By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Verona Pharma 

Suite 21 - Alpha House
100 Borough High Street
London    SE1 1LB  United Kingdom
Phone: 44-0-20-7863-3300 Fax: 44-0-20-7863-3314



Life Sciences

Company News
Verona Pharma (VRP.L) Release: Paper Demonstrating That RPL554 Enhances CTFR Activation In Cystic Fibrosis Airway Epithelia Published In American Journal Of Physiology 11/11/2015 10:06:02 AM
Verona Pharma (VRP.L) Release: Completion Of Patient Enrolment In Two RPL554 Phase IIa Studies, Ahead Of Expected Timeline 11/5/2015 11:29:25 AM
Verona Pharma (VRP.L) Presents At BIO-Europe Partnering Conference 11/3/2015 9:24:12 AM
Verona Pharma (VRP.L) Announces Start Of RPL554 Phase IIa Combination Study 10/14/2015 11:22:11 AM
Verona Pharma (VRP.L) Data Demonstrating PDE3/4 Inhibitor RPL554 Enhances CTFR-Dependent Currents In Cystic Fibrosis Airway Epithelia 10/8/2015 10:17:09 AM
Verona Pharma (VRP.L) Positive Headline Data From RPL554 Clinical Study In COPD Patients 9/29/2015 9:36:04 AM
Verona Pharma (VRP.L) Appoints Dr Ken Cunningham And Dr Anders Ullman As Non-Executive Directors 9/8/2015 10:51:28 AM
Verona Pharma (VRP.L) Release: Interim Results For The Six Months Ended 30 June 2015 9/8/2015 10:46:49 AM
Verona Pharma (VRP.L) Release: Secondary Listing To Provide Trading Facility On Xetra Exchange In Germany 6/12/2015 8:58:33 AM
Verona Pharma (VRP.L) Release: RPL554 Phase 2a Trial Started; Headline Data Expected Q1 2016 6/11/2015 9:23:13 AM